KP Tissue Inc. (KPT) (TSX: KPT) reports the Q2 2023 financial and operational results of KPT and Kruger Products Inc. (Kruger Products). Kruger Products is Canada's leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and BonterraTM) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 13.3% interest in Kruger Products.

Kruger Products Q2 2023 Business and Financial Highlights

  • Revenue was $466.3 million in Q2 2023 compared to $397.5 million in Q2 2022, an increase of $68.8 million or 17.3%.
  • Adjusted EBITDA1 was $55.0 million in Q2 2023, compared to $11.8 million in Q2 2022, an increase of 365.8%.
  • Net income was $14.5 million in Q2 2023 compared to a net loss of $35.5 million in Q2 2022, an increase of $50.0 million.
  • Declared a quarterly dividend of $0.18 per share to be paid on October 16, 2023.

“We are pleased that margin recovery, along with improved sales volume and a better mix in our Consumer business, generated strong Adjusted EBITDA of $55.0 million in the second quarter of 2023,” stated KP Tissue’s Chief Executive Officer, Dino Bianco. “Ongoing cost management initiatives, including productivity gains and cost controls, also contributed to increasing profitability. In addition, our Away-From-Home segment delivered a fourth consecutive quarter of positive Adjusted EBITDA to maintain its growth momentum. As a result, our financial performance in the second quarter normalized versus a more challenging market and operating environment in the same period last year. On a sequential basis, revenue and Adjusted EBITDA continued to improve, rising 3.4% and 10.2% in the quarter, respectively.”

“Looking ahead to the second half of 2023, we anticipate a more favourable landscape as input costs trend downwards, TAD Sherbrooke and the Sherbrooke Expansion Project continue to ramp up production capacity to meet customer demand, and margins are restored to their pre-pandemic levels,” Mr. Bianco added.

Outlook for Q3 2023For the third quarter of 2023, as commodity and other input costs begin to decline, we will focus on maintaining our margins while also continuing to reinvest in the business to drive long-term value. Accordingly, Adjusted EBITDA1 in Q3 2023 is expected to be in the range of Q2 2023.

Kruger Products Q2 2023 Financial ResultsRevenue was $466.3 million in Q2 2023 compared to $397.5 million in Q2 2022, an increase of $68.8 million or 17.3%. The increase in revenue was primarily due to the favourable impact of selling price increases implemented across all segments and regions during 2022, along with favourable sales mix and higher sales volume in the Consumer business. Revenue was also favourably impacted by foreign exchange fluctuations on U.S. dollar sales.

Cost of sales was $395.8 million in Q2 2023 compared to $372.5 million in Q2 2022, an increase of $23.3 million or 6.2%. Higher sales volumes increased cost of sales, along with the unfavourable impact of foreign exchange fluctuations on U.S. dollar costs, partially offset by improvements in Memphis operations. While the significant inflation experienced during 2022 has moderated in the second quarter of 2023, manufacturing input costs remain higher than the year ago quarter. Freight rates were lower compared to Q2 2022 as supply constraints and inflation moderated, while warehousing costs increased as a result of additional logistics network costs. As a percentage of revenue, cost of sales was 84.9% in Q2 2023 compared to 93.7% in Q2 2022.

Selling, general and administrative (SG&A) expenses were $40.6 million in Q2 2023 compared to $35.1 million in Q2 2022, an increase of $5.5 million or 15.7%. The increase was primarily due to higher personnel costs, foreign exchange losses related to foreign denominated working capital and a loss on disposal of fixed assets, partially offset by lower advertising spend in the quarter. As a percentage of revenue, SG&A expenses were 8.7% in Q2 2023 compared to 8.8% in Q2 2022.

Adjusted EBITDA1 was $55.0 million in Q2 2023 compared to $11.8 million in Q2 2022, an increase of $43.2 million or 365.8%. The significant increase was primarily due to a combination of factors: selling price increases in 2022, favourable sales mix along with higher sales volumes, improvements in Memphis operations and lower freight rates. These factors were partially offset by inflation on input costs compared to Q2 2022, higher warehousing and SG&A expenses and the unfavourable impact of foreign exchange fluctuations.

Net income was $14.5 million in Q2 2023 compared to a loss of $35.5 million in Q2 2022, an increase of $50.0 million. The increase was primarily due to higher Adjusted EBITDA1 and higher foreign exchange gains, partially offset by higher income tax and depreciation expenses, higher interest expense and other finance costs and a loss on sale of fixed assets.

1 Adjusted EBITDA is a non-GAAP financial measure. Refer to the Non-GAAP Financial Measures section of this news release for more information on these measures

Kruger Products Q2 2023 LiquidityTotal liquidity, representing cash and availability under the revolving credit agreements, was $181.5 million as of June 30, 2023. In addition, $13.8 million of cash was held by Kruger Products for the Sherbrooke Expansion Project.

KPT Q2 2023 Financial ResultsKPT had net income of $2.0 million in Q2 2023. Included in net income was $2.1 million representing KPT’s share of Kruger Products’ net income, a dilution gain of $0.2 million and depreciation expense of $0.3 million related to adjustments to carrying amounts on acquisition.

Dividends on Common SharesThe Board of Directors of KPT declared a quarterly dividend of $0.18 per share to be paid on October 16, 2023 to shareholders of record at the close of business on October 2, 2023.

Additional InformationFor additional information please refer to Management’s Discussion and Analysis (MD&A) of KPT and Kruger Products for the second quarter ended June 30, 2023 available on SEDAR at www.sedar.com or our website at www.kptissueinc.com.

Second Quarter Results Conference Call InformationKPT will hold its second quarter conference call on Thursday, August 10, 2023 at 8:30 a.m. Eastern Time.

Via telephone: 1-800-319-4610 or 604-638-5340

Via the internet at: www.kptissueinc.com

Presentation material referenced during the conference call will be available at www.kptissueinc.com.

A rebroadcast of the conference call will be available until midnight, August 17, 2023 by dialing 1-855-669-9658 or 604-674-8052 and entering passcode 0272.

The replay of the webcast will remain available on the website until midnight, August 17, 2023.

About KP Tissue Inc. (KPT)KPT was created to acquire, and its business is limited to holding, a limited equity interest in Kruger Products, which is accounted for as an investment on the equity basis. KPT currently holds a 13.3% interest in Kruger Products. For more information visit www.kptissueinc.com.

About Kruger ProductsKruger Products is Canada's leading manufacturer of quality tissue products for household, industrial and commercial use. Kruger Products serves the Canadian consumer market with such well-known brands as Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and BonterraTM. In the U.S., Kruger Products manufactures the White Cloud® brand, as well as many private label products. The Away-From-Home division manufactures and distributes high-quality, cost-effective product solutions to a wide range of commercial and public entities. Kruger Products has approximately 2,700 employees and operates nine FSC® COC-certified (FSC® C-104904) production facilities in North America. For more information visit www.krugerproducts.ca.

Non-GAAP Financial MeasuresThis press release uses certain non-GAAP financial measures which Kruger Products believes provide useful information to management of Kruger Products and the readers of the financial information in measuring the financial performance and financial condition of Kruger Products. These measures do not have a standardized meaning prescribed by GAAP and therefore may not be comparable to similarly titled measures presented by other companies. An example of such a measure is Adjusted EBITDA. Adjusted EBITDA is not a measurement of operating performance computed in accordance with GAAP and should not be considered as a substitute for operating income, net income or cash flows from operating activities computed in accordance with GAAP. “Adjusted EBITDA” is calculated by Kruger Products as net income (loss) before (i) interest expense and other finance costs, (ii) income taxes, (iii) depreciation, (iv) amortization, (v) impairment (gain on sale) of non-financial assets, (vi) loss (gain) on disposal of property, plant and equipment, (vii) foreign exchange loss (gain), (viii) costs related to restructuring activities, (ix) changes in amortized cost of Partnership units liability, (x) change in fair value of derivatives, (xi) consulting costs related to operational transformation initiatives, (xii) corporate development related costs and (xiii) loss (gain) on sale of shares. A reconciliation of Adjusted EBITDA to the relevant reported results can be found in the Segment and Geographic Results table of this news release.

Forward-Looking StatementsCertain statements in this press release about KPT’s and Kruger Products' current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding continued growth in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products, the expected impact of our Sherbrooke Expansion Project, the expected start-up dates of the facial tissue line and paper machine of the Sherbrooke Expansion Project, expected growth and profitability in 2023 and our expectation that Adjusted EBITDA1 in Q3 2023 will be in the range of Q2 2023. The words "may", "will", "would", "should", "could", "expects", "plans", "intends", "trends", "indications", "anticipates", "believes", "estimates", "predicts", "likely" or "potential" or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. The forward-looking statements are based on certain key expectations and assumptions made by KPT or Kruger Products, including that inflationary pressure has stabilized. Although KPT and Kruger Products believe that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking statements since no assurance can be given that such expectations and assumptions will prove to be correct.

The outlook provided in respect of Adjusted EBITDA1 for Q3 2023 and expected growth and profitability in 2023 is forward-looking information and is based on the assumptions and subject to the risk and uncertainties referred to below. The purpose of the outlook is to provide the reader with an indication of management’s expectations, at the date of this press release, regarding Kruger Products’ future financial performance. Readers are cautioned that this information may not be appropriate for other purposes.

Many factors could cause Kruger Products’ actual results, level of activity, performance or achievements or future events or developments (which could in turn affect the economic benefits derived from KPT’s economic interest in Kruger Products), to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the following factors, which are discussed in greater detail in the “Risk Factors – Risks Related to Kruger Products’ Business” section of the KPT Annual Information Form dated March 9, 2023 available on SEDAR at www.sedar.com; Kruger Inc.’s influence over Kruger Products; Kruger Products’ reliance on Kruger Inc.; consequences of an event of insolvency relating to Kruger Inc.; risks associated with the TAD Sherbrooke Project; risks associated with the Sherbrooke Expansion Project; operational risks; significant increases in input costs; reduction in supply of fibre; increased pricing pressure and intense competition; Kruger Products’ inability to innovate effectively; adverse economic conditions; dependence on key retail trade customers; damage to the reputation of Kruger Products or Kruger Products’ brands; Kruger Products’ sales being less than anticipated; Kruger Products’ failure to implement its business and operating strategies; Kruger Products’ obligation to make regular capital expenditures; Kruger Products’ entering into unsuccessful acquisitions; Kruger Products’ dependence on key personnel; Kruger Products’ inability to retain its existing customers or obtain new customers; Kruger Products’ loss of key suppliers; Kruger Products’ failure to adequately protect its intellectual property rights; Kruger Products’ reliance on third party intellectual property licenses; adverse litigation and other claims affecting Kruger Products; material expenditures due to comprehensive environmental regulation affecting Kruger Products’ cash flow; Kruger Products’ pension obligations are significant and can be materially higher than predicted if Kruger Products Management’s underlying assumptions are incorrect; labour disputes adversely affecting Kruger Products’ cost structure and Kruger Products’ ability to run its plants; exchange rate and U.S. competitors; Kruger Products’ inability to service all of its indebtedness; exposure to potential consumer product liability; covenant compliance; interest rate and refinancing risk; and risks relating to information technology; cyber-security; insurance; internal controls; trade; and risks related to COVID-19.

Readers should not place undue reliance on forward-looking statements made herein. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. The forward-looking information contained herein is made as of the date of press release and KPT undertakes no obligation to publicly update such forward-looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws.

INFORMATION:

Francois ParoyanGeneral Counsel and Corporate SecretaryKP Tissue Inc.Tel.: 905.812.6936francois.paroyan@krugerproducts.ca

INVESTORS:

Mike BaldesarraDirector of Investor RelationsKP Tissue Inc.Tel.: 905.812.6962IR@KPTissueinc.com

Kruger Products Inc.
Unaudited Condensed Consolidated Statements of Financial Position
(thousands of Canadian dollars)
         
         
    June 30, 2023     December 31, 2022  
    $     $  
Assets      
Current assets      
  Cash and cash equivalents 88,245     71,261  
  Restricted cash 9,702     7,145  
  Trade and other receivables 118,777     119,681  
  Receivables from related parties 245     223  
  Inventories 262,509     286,566  
  Income tax recoverable 4,119     1,306  
  Prepaid expenses 14,301     5,640  
    497,898     491,822  
Non-current assets      
  Property, plant and equipment 1,321,358     1,294,838  
  Right-of-use assets 78,066     81,715  
  Other long-term assets 13,843     27,554  
  Pensions 80,264     83,080  
  Goodwill 152,021     152,021  
  Intangible assets 28,374     30,027  
  Deferred income taxes 29,375     95,711  
Total assets 2,201,199     2,256,768  
         
Liabilities      
Current liabilities      
  Trade and other payables 277,667     279,425  
  Payables to related parties 9,633     11,363  
  Dividends payable 13,261     -  
  Distributions payable -     12,866  
  Current portion of long-term debt 34,134     34,411  
  Current portion of lease liabilities 28,313     28,349  
  Current portion of long-term payable to related party 5,800     5,800  
  Current portion of provisions 2,737     3,252  
    371,545     375,466  
Non-current liabilities      
  Long-term debt 1,077,746     1,077,297  
  Long-term lease liabilities 65,253     70,579  
  Long-term payable to related party 34,460     39,042  
  Long-term provisions 2,863     3,076  
  Pensions 20,555     20,847  
  Post-retirement benefits 46,244     43,739  
  Liabilities to non-equityholders 1,618,666     1,630,046  
  Long-term portion of Partnership units liability -     133,551  
  Total Partnership units liability -     133,551  
Total liabilities 1,618,666     1,763,597  
         
Equity      
  Share capital 650,469     -  
  Partnership units -     494,459  
  Deficit (158,661 )   (87,835 )
  Accumulated other comprehensive income 81,295     86,547  
  Equity attributable to Kruger Products 573,103     493,171  
  Non-controlling interest 9,430     -  
Total equity 582,533     493,171  
Total equity and liabilities 2,201,199     2,256,768  
         
Kruger Products Inc.
Unaudited Condensed Consolidated Statements of Income (Loss)
(thousands of Canadian dollars)
               
               
  3-month period ended June 30, 2023   3-month period ended June 30, 2022   6-month period ended June 30, 2023   6-month period ended June 30, 2022
  $   $   $   $
               
Revenue 466,302     397,499     917,294     796,238  
               
Expenses              
Cost of sales 395,712     372,489     784,736     736,344  
Selling, general and administrative expenses 40,640     35,111     76,901     63,966  
Loss on sale of non-financial assets 13     5     16     10  
Restructuring costs, net 84     352     1,223     868  
               
Operating income (loss) 29,853     (10,458 )   54,418     (4,950 )
               
Interest expense and other finance costs 18,539     17,369     35,063     34,903  
Other (income) expense (8,849 )   12,599     (9,265 )   8,284  
               
Income (loss) before income taxes 20,163     (40,426 )   28,620     (48,137 )
               
Income tax expense (recovery) 5,162     (4,913 )   63,735     (14,061 )
               
Net income (loss) including non-controlling interest 15,001     (35,513 )   (35,115 )   (34,076 )
               
Net income (loss) attributable to non-controlling interest 517     -     (338 )   -  
               
Net income (loss) attributable to Kruger Products 14,484     (35,513 )   (34,777 )   (34,076 )
               
Kruger Products Inc.
Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss)
(thousands of Canadian dollars)
               
               
  3-month period ended June 30, 2023   3-month period ended June 30, 2022   6-month period ended June 30, 2023   6-month period ended June 30, 2022
  $   $   $   $
               
Net income (loss) including non-controlling interest 15,001     (35,513 )   (35,115 )   (34,076 )
               
               
Other comprehensive income (loss)              
Items that will not be reclassified to net income     (loss):              
Remeasurements of pensions (4,037 )   89,304     (19,881 )   194,925  
Remeasurements of post-retirement benefits (452 )   6,190     10,190     14,051  
Items that may be subsequently reclassified to     net income (loss):                
Cumulative translation adjustment (5,040 )   8,422     (5,252 )   4,385  
               
Other comprehensive income (loss) (9,529 )   103,916     (14,943 )   213,361  
               
Total comprehensive income (loss) including     non-controlling interest 5,472     68,403     (50,058 )   179,285  
Total comprehensive income (loss) attributable to     non-controlling interest 517     -     (338 )   -  
               
Total comprehensive income (loss) attriutable to     Kruger Products 4,955     68,403     (49,720 )   179,285  
               
Kruger Products Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
(thousands of Canadian dollars)
               
               
               
  3-month period ended June 30, 2023   3-month period ended June 30, 2022   6-month period ended June 30, 2023   6-month period ended June 30, 2022
  $   $   $   $
Cash flows from (used in) operating activities              
Net income (loss) including non-controlling interest 15,001     (35,513 )   (35,115 )   (34,076 )
Items not affecting cash              
Depreciation 22,889     20,778     46,078     42,760  
Amortization 1,096     1,125     2,161     2,169  
Loss on sale of property, plant and equipment 1,114     18     1,109     18  
Gain on disposal of leased assets -     -     (488 )   -  
Foreign exchange (gain) loss (8,849 )   12,599     (9,265 )   8,284  
Interest expense and other finance costs 18,539     17,369     35,063     34,903  
Pension and post-retirement benefits 2,224     3,576     4,112     7,270  
Provisions 508     733     1,939     494  
Income tax expense (recovery) 5,162     (4,913 )   63,735     (14,061 )
Loss on sale of non-financial assets 13     5     16     10  
Total items not affecting cash 42,696     51,290     144,460     81,847  
               
Net change in non-cash working capital 68,307     (20,031 )   16,858     (66,521 )
Contributions to pension and post-retirement benefit plans (2,680 )   (4,157 )   (5,198 )   (8,340 )
Provisions paid (2,585 )   (3,733 )   (3,274 )   (3,915 )
Income tax payments, net (1,621 )   (1,168 )   (1,458 )   (1,488 )
Net cash from (used in) operating activities 119,118     (13,312 )   116,273     (32,493 )
               
Cash flows from (used in) investing activities              
Purchases of property, plant and equipment (4,669 )   (18,431 )   (8,680 )   (18,930 )
Purchases of property, plant and equipment and software     related to the TAD Sherbrooke Project (743 )   (5,598 )   (743 )   (10,929 )
Purchases of property, plant and equipment related to the     Sherbrooke Expansion Project (36,798 )   (14,704 )   (68,460 )   (20,748 )
Interest paid on credit facilities related to the Sherbrooke     Expansion Project (119 )   (306 )   (216 )   (306 )
Government assistance received -     -     1,250     -  
Purchases of software (437 )   (304 )   (508 )   (4,759 )
Proceeds on sale of property, plant and equipment 2,443     1     2,448     1  
Net cash used in investing activities (40,323 )   (39,342 )   (74,909 )   (55,671 )
               
Cash flows from (used in) financing activities              
Proceeds from long-term debt 21,281     75,550     56,782     217,506  
Repayment of long-term debt (14,874 )   (6,907 )   (23,569 )   (125,446 )
Payment of deferred financing fees (134 )   823     (380 )   (1,312 )
Payment of lease liabilities (7,046 )   (7,426 )   (13,796 )   (14,411 )
Change in Restricted cash (1,332 )   (1,166 )   (2,557 )   (2,312 )
Interest paid on long-term debt (17,641 )   (16,094 )   (31,360 )   (24,987 )
Payment to related party (5,700 )   -     (5,700 )   -  
Dividends paid, net (1,761 )   -     (3,504 )   -  
Distributions and advances paid, net -     (7,046 )   -     (14,021 )
Net cash from (used in) financing activities (27,207 )   37,734     (24,084 )   35,017  
               
Effect of exchange rate changes on cash and cash              
equivalents held in foreign currency (259 )   426     (296 )   160  
               
Increase (decrease) in cash and cash equivalents     during the period 51,329     (14,494 )   16,984     (52,987 )
               
Cash and cash equivalents - Beginning of period 36,916     110,026     71,261     148,519  
               
Cash and cash equivalents - End of period 88,245     95,532     88,245     95,532  
               
Kruger Products Inc.
Segment and Geographic Results
(thousands of Canadian dollars)
                 
                 
    3-month period ended June 30, 2023   3-month period ended June 30, 2022   6-month period ended June 30, 2023   6-month period ended June 30, 2022
    $   $   $   $
                 
Segment Information                
                 
Segment Revenue                
Consumer   383,477     326,333     759,997     669,175  
AFH   82,825     71,166     157,297     127,063  
                 
Total segment revenue   466,302     397,499     917,294     796,238  
                 
Adjusted EBITDA                
Consumer   53,308     14,298     104,642     49,681  
AFH   5,834     (451 )   6,718     (3,672 )
Corporate and other costs   (4,093 )   (2,027 )   (6,355 )   (5,134 )
                 
Total Adjusted EBITDA   55,049     11,820     105,005     40,875  
                 
Reconciliation to net income (loss):                
                 
Depreciation and amortization   23,985     21,903     48,239     44,929  
Interest expense and other finance costs   18,539     17,369     35,063     34,903  
Loss on sale of property, plant and equipment   1,114     18     1,109     18  
Loss on sale of non-financial assets   13     5     16     10  
Restructuring costs, net   84     352     1,223     868  
Foreign exchange (gain) loss   (8,849 )   12,599     (9,265 )   8,284  
                 
Income (loss) before income taxes   20,163     (40,426 )   28,620     (48,137 )
                 
Income tax recovery   5,162     (4,913 )   63,735     (14,061 )
                 
Net income (loss)   15,001     (35,513 )   (35,115 )   (34,076 )
                 
Geographic Revenue                
                 
Canada   265,165     239,286     525,945     482,206  
US   201,137     158,213     391,349     314,032  
                 
Total revenue   466,302     397,499     917,294     796,238  
                 
KP Tissue Inc.
Unaudited Condensed Statements of Financial Position
(thousands of Canadian dollars)
       
       
  June 30, 2023     December 31, 2022  
  $     $  
Assets      
       
Current assets      
Dividends receivable 1,791     -  
Distributions receivable -     1,790  
Income tax recoverable 580     580  
  2,371     2,370  
       
Non-current assets      
Investment in associate 68,785     79,338  
       
Total assets 71,156     81,708  
       
Liabilities      
       
Current liabilities      
Dividend payable 1,791     1,790  
Payable to investee 170     -  
Payable to Partnership -     170  
  1,961     1,960  
Non-current liabilities      
Deferred income taxes -     5,718  
       
Total liabilities 1,961     7,678  
       
Equity      
       
Common shares 22,458     22,379  
Contributed surplus 144,819     144,819  
Deficit (114,188 )   (108,008 )
Accumulated other comprehensive income 16,106     14,840  
       
Total equity 69,195     74,030  
       
Total liabilities and equity 71,156     81,708  
       
KP Tissue Inc.
Unaudited Condensed Statements of Income (Loss) and Comprehensive Income (Loss)
(thousands of Canadian dollars, except share and per share amounts)
               
  3-month period ended June 30, 2023   3-month period ended June 30, 2022   6-month period ended June 30, 2023   6-month period ended June 30, 2022
  $   $   $   $
               
Equity income (loss) 1,761     (6,423 )   (5,298 )   (7,531 )
Dilution gain 252     127     525     200  
               
Income (loss) before income taxes 2,013     (6,296 )   (4,773 )   (7,331 )
               
Income tax expense (recovery) -     (2,348 )   3,892     (4,361 )
               
Net income (loss) 2,013     (3,948 )   (8,665 )   (2,970 )
               
Other comprehensive income     (loss)              
net of tax expense     (recovery)              
Items that will not be reclassified     to net income (loss):              
Remeasurements of pensions (514 )   7,884     4,209     18,132  
Remeasurements of post-retirement benefits (82 )   729     1,859     1,399  
Items that may be subsequently reclassified     to net income (loss):                
Cumulative translation adjustment (817 )   1,186     1,266     591  
               
Other comprehensive income (loss) (1,413 )   9,799     7,334     20,122  
               
Total comprehensive income (loss) 600     5,851     (1,331 )   17,152  
               
Basic earnings (loss) per share 0.20     (0.40 )   (0.87 )   (0.30 )
               
Weighted average number of shares outstanding 9,953,131     9,935,108     9,951,513     9,930,492  
               
KP Tissue Inc.
Unaudited Condensed Statements of Cash Flows
(thousands of Canadian dollars)
               
  3-month period ended June 30, 2023   3-month period ended June 30, 2022   6-month period ended June 30, 2023   6-month period ended June 30, 2022
  $   $   $   $
Cash flows from (used in) operating activities              
Net income (loss) 2,013     (3,948 )   (8,665 )   (2,970 )
Items not affecting cash              
Equity loss (income) (1,761   6,423     5,298     7,531  
Dilution gain (252 )   (127 )   (525 )   (200 )
Income tax expense (recovery) -     (2,348 )   3,892     (4,361 )
Total items not affecting cash (2,013   3,948     8,665     2,970  
               
Net change in non-cash working capital -     (169   -     (169 )
Tax payments, net -     169     -     131  
Tax Distribution received, net -     -     -     38  
               
Net cash from (used in) operating activities -     -     -     -  
               
Cash flows from investing activities              
Dividends received 1,761      -     3,503      
Partnership unit distributions received -     1,741     -     3,144  
               
Net cash from investing activities 1,761     1,741     3,503     3,144  
               
Cash flows used in financing activities              
Dividends paid, net (1,761 )   (1,741 )   (3,503 )   (3,144 )
               
Net cash used in financing activities (1,761 )   (1,741 )   (3,503 )   (3,144 )
               
Increase (decrease) in cash and cash equivalents     during the period -     -     -     -  
               
Cash and cash equivalents - Beginning of period -     -     -     -  
               
Cash and cash equivalents - End of period -     -     -     -  
 
KP Tissue (TSX:KPT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more KP Tissue Charts.
KP Tissue (TSX:KPT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more KP Tissue Charts.